Tags

Type your tag names separated by a space and hit enter

Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.
J Korean Med Sci. 2017 Mar; 32(3):475-479.JK

Abstract

Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-Müllerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone age-matched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function.

Authors+Show Affiliations

Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.Department of Pediatrics, Korea University College of Medicine, Seoul, Korea. khlee218@kumc.or.kr.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28145651

Citation

Nam, Hyo Kyoung, et al. "Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls According to Stage of GnRH Agonist Treatment." Journal of Korean Medical Science, vol. 32, no. 3, 2017, pp. 475-479.
Nam HK, Kim HR, Rhie YJ, et al. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment. J Korean Med Sci. 2017;32(3):475-479.
Nam, H. K., Kim, H. R., Rhie, Y. J., & Lee, K. H. (2017). Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment. Journal of Korean Medical Science, 32(3), 475-479. https://doi.org/10.3346/jkms.2017.32.3.475
Nam HK, et al. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls According to Stage of GnRH Agonist Treatment. J Korean Med Sci. 2017;32(3):475-479. PubMed PMID: 28145651.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment. AU - Nam,Hyo Kyoung, AU - Kim,Hye Ryun, AU - Rhie,Young Jun, AU - Lee,Kee Hyoung, PY - 2016/09/08/received PY - 2016/12/03/accepted PY - 2017/03/01/pmc-release PY - 2017/2/2/entrez PY - 2017/2/2/pubmed PY - 2017/4/1/medline KW - Anti-Müllerian Hormone KW - Gonadotropin-Releasing Hormone Agonist KW - Ovarian Reserve KW - Puberty, Precocious SP - 475 EP - 479 JF - Journal of Korean medical science JO - J. Korean Med. Sci. VL - 32 IS - 3 N2 - Few studies have investigated the long-term effects of gonadotropin-releasing hormone (GnRH) agonist treatment on the reproductive function of central precocious puberty (CPP) girls. In this cross-sectional study, we assessed the ovarian function by analyzing the serum anti-Müllerian hormone (AMH) levels of CPP girls. Our study included 505 CPP girls subdivided into 5 groups according to the GnRH agonist treatment stage: group A (before treatment, n = 98), group B (3 months after initiation, n = 103), group C (12 months after initiation, n = 101), group D (24 months after initiation, n = 101), and group E (6 months after discontinuation, n = 102). We compared the serum AMH levels of the CPP girls with those of 100 bone age-matched controls (before treatment: n = 55; after discontinuation: n = 45). At baseline, the mean AMH level of the CPP girls was 5.9 ± 3.6 ng/mL. The mean AMH level after 3 months of the GnRH agonist treatment was lower (4.7 ± 3.2 ng/mL, P = 0.047) than that at baseline and recovered after 12 months of treatment. Six months after discontinuation, the AMH levels were similar to those at pre-treatment. Before and after the GnRH agonist treatment, the AMH levels were similar to those of the bone age-matched controls. In the precocious puberty girls, the AMH levels based on the GnRH agonist treatment stage were all within the normal reference range. The results of this study suggest that GnRH agonist treatment has no adverse effects on the reproductive function. SN - 1598-6357 UR - https://www.unboundmedicine.com/medline/citation/28145651/Serum_Anti_Müllerian_Hormone_Levels_in_Precocious_Puberty_Girls_according_to_Stage_of_GnRH_Agonist_Treatment_ L2 - https://jkms.org/DOIx.php?id=10.3346/jkms.2017.32.3.475 DB - PRIME DP - Unbound Medicine ER -